Companies: 10,795·Total market cap: $144.5T
Bicycle Therapeutics plc

Bicycle Therapeutics plc

BCYCNASDAQHealthcare● Active
$4.20
$-0.07(-1.64%)
Market Cap$291457047
P/E Ratio
52W High$9.36
52W Low$4.075

Bicycle Therapeutics plc (BCYC) Stock Forecast & Analyst Price Target

Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.

bcyc · stock forecast · 21 analysts (3M) · FMP · updated Jun 8, 2026

Analyst Rating & Consensus

Based on 21 Wall Street analysts in the past 3 months

SellBuy

Buy

21 analysts

consensus

Rating Breakdown

Strong Buy
0
Buy
17
Hold
4
Sell
0
Strong Sell
0
Total: 21 · Buy rate: 81.0%

12-Month Price Target

High

$12.00

Consensus

$10.67

+154.0% upside

Low

$8.00

Median: $12 · Last Close: $4.20

The Bicycle Therapeutics plc (BCYC) analyst consensus is Buy, based on ratings from 21 Wall Street analysts over the past 3 months. The average 12-month BCYC price target is $10.67, representing +154.0% upside from the current price of $4.20.

12-Month Price Target Forecast

Historical closing prices + analyst 12-month price target forecast cone

Historical priceConsensus $11 (154.0%)

Consensus Target

$10.67

154.0% upside

High Target

$12

185.7%

Low Target

$8

90.5%

Current Price

$4.20

as of today

Based on analyst price targets, the BCYC stock price prediction for the next 12 months ranges from $8 to $12. The consensus BCYC price forecast of $10.67 implies 154.0% upside from the current price of $4.20.

Short-Term Price Prediction

Low Activity

Algorithmically generated · Updated daily

DatePredicted PriceChange
2026-06-09$4.092.67%

1-day model range: $4.04–$4.13. Peak: $4.13 (-2.67%).

Long-Term Stock Price Prediction

Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031

YearAvg PriceChange
2027-50.0%
2028-62.5%
2029-67.2%
2030-69.2%
2031-70.2%
Confidence:Very Low
⚠️ 2027 projections carry Very Low confidence. Treat as directional guidance only.

Stock Forecast Based on Technical Analysis

14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency

🚫

Insufficient Trading Activity — Sentiment Signals Disabled

This stock has very low trading volume (ZOMBIE condition). Sentiment analysis requires sufficient price action. RSI and MACD values below are still shown for reference.

RSI (14)38.3
MACDBEARISH

Moving Averages · BCYC · Jun 8, 2026

Simple Moving Average (SMA)
MA 5$4.30SELL
MA 10$4.46SELL
MA 20$4.51SELL
MA 50$4.74SELL
MA 100$5.21SELL
MA 200$6.23SELL
Current $BCYC · Price above MA = BUY signal
Exponential Moving Average (EMA)
EMA 5$4.30SELL
EMA 10$4.39SELL
EMA 20$4.51SELL
EMA 50$4.76SELL
EMA 100$5.24SELL
EMA 200$6.40SELL
Current $BCYC · Price above MA = BUY signal
How we calculate: Technical sentiment is derived from 14 indicators — SMA(5,10,20,50,100,200), EMA(5,10,20,50,100,200), RSI(14), and MACD(12,26,9) — calculated from historical EOD price data. BUY = current price above MA; SELL = below. 14 TA signals + historical EOD price data · Updated daily. Independent of analyst consensus data. Not investment advice.

Latest Analyst Ratings & Upgrades

Filter:
Morgan Stanley2026-04-08
Maintains
Equal WeightEqual Weight
RBC Capital2026-03-18
Maintains
Sector PerformSector Perform
Needham2026-03-18
Maintains
BuyBuy
Oppenheimer2026-03-18
Maintains
OutperformOutperform
Citizens2026-03-18
Maintains
Market OutperformMarket Outperform
Citizens2025-10-31
Maintains
Market OutperformMarket Outperform
RBC Capital2025-10-31
Downgrade ↓
OutperformSector Perform
Morgan Stanley2025-08-12
Maintains
Equal WeightEqual Weight
JMP Securities2025-08-12
Maintains
Market OutperformMarket Outperform
Oppenheimer2025-08-11
Maintains
OutperformOutperform

Wall Street analysts have recently issued updated ratings on Bicycle Therapeutics plc (BCYC) stock. Of the recent 106 rating actions, 3 were upgrades and 3 were downgrades. 21 analysts currently cover BCYC.

Analyst Recommendation Trends

Buy ratings404
Hold ratings211
Sell ratings00

BCYC analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 4 to 0 per month.

Financial Forecast: EPS & Revenue Estimates

Revenue This Year

$22M

↓ 61.5% YoY

Revenue Next Year

$15M

↓ 32.7% YoY

EPS This Year

$-2.31

EPS Next Year

$-2.36

↑ 2.3% YoY

EPS ForecastReported vs Estimated

Reported EPSHistorical estimateAnalyst forecast (future)

Analysts forecast BCYC EPS of $-2.31 for the current fiscal year, based on estimates from 8 analysts. The BCYC revenue forecast is $22M for the current year. These are analyst consensus estimates via FMP / S&P Global.

About Forecast & Price Prediction

The BCYC stock forecast is supported by two independent data sources: analyst consensus ratings from 21 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus BCYC price target is $10.67 (+154.0% upside), with an analyst consensus of Buy.

The BCYC short-term stock prediction for tomorrow is $4.09 (-2.67%). The BCYC stock prediction for 2030 projects a range of $1–$1.

Bicycle Therapeutics plc trades on NASDAQ under the ticker BCYC. The BCYC stock outlook for 2027 is broadly positive, supported by a Buy consensus among 81% of covering analysts.

FAQ answers synthesize analyst targets, estimates, and on-page model outputs where shown.

Frequently asked questions

BCYC forecast · 8 questions

According to 21 Wall Street analysts, the average 12-month BCYC price target is $10.67, with a high forecast of $12.00 and a low of $8.00. The median price target is shown in the chart above when available. This implies +154.0% potential upside from the current price of $4.20.

BCYC price targetWhat is BCYC price targetBCYC analyst price targetBCYC 12-month target

· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)

⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.